Breast cancer in young women (YBC): Prevalence of BRCA1/2 mutations and risk of secondary malignancies across diverse racial groups

Annals of Oncology

Volumn 20, Issue 10, 2009, Pages 1653-1659

  Haffty, B G ^a   Choi, D H ^b   Goyal, S ^a   Silber, A ^c   Ranieri, K ^d   Matloff, E ^c   Lee, M H ^e   Nissenblatt, M ^d   Toppmeyer, D ^d   Moran, M S ^c  

^a ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

^b Sungkyunkwan University School of Medicine   (South Korea)

^c YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d RUTGERS CANCER INSTITUTE OF NEW JERSEY   (United States)

^e Soonchunhyang University College of Medicine   (South Korea)

Author keywords

BRCA1; BRCA2; Breast cancer; Genetics; Race

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN;

ADULT; AFRICAN AMERICAN; ARTICLE; ASIAN; BREAST CANCER; CANCER RISK; CAUCASIAN; CONTROLLED STUDY; FAMILY HISTORY; FEMALE; GENE FREQUENCY; GENE MUTATION; GENE SEQUENCE; GENETIC ANALYSIS; GENETIC PREDISPOSITION; GENETIC SIMILARITY; GENETIC VARIABILITY; HUMAN; KOREA; MAJOR CLINICAL STUDY; METASTASIS POTENTIAL; MUTATION RATE; ONSET AGE; PRIORITY JOURNAL; RACE DIFFERENCE; SEQUENCE ANALYSIS;

ADULT; AFRICAN AMERICANS; AGE OF ONSET; ASIAN CONTINENTAL ANCESTRY GROUP; BRCA1 PROTEIN; BRCA2 PROTEIN; BREAST NEOPLASMS; DNA MUTATIONAL ANALYSIS; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; HUMANS; MUTATION; NEOPLASMS, SECOND PRIMARY; PREVALENCE; RISK FACTORS;

EID: 70349651005     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdp051     Document Type: Article

References (46)

1. El-Tamer MB, Wait RB. Age at presentation of African-American and Caucasian breast cancer patients. J Am Coll Surg 1999; 188: 237-240.
2. Jemal A, Siegel R, Ward E et al. Cancer statistics, 2006. CA Cancer J Clin 2006; 56: 106-130.
3. Ahn SH. Clinical characteristics of breast cancer patients in Korea in 2000. Arch Surg 2004; 139: 27-30discussion 31.
4. MacMahon B. Epidemiology and the causes of breast cancer. Int J Cancer 2006; 118: 2373-2378.
5. Gao Q, Tomlinson G, Das S et al. Prevalence of BRCA1 and BRCA2 mutations among clinic-based African American families with breast cancer. Hum Genet 2000; 107: 186-191.
6. Haffty B, Silber A, Matloff E et al. Racial differences in the incidence of BRCA1 and BRCA2 mutations in a cohort of early onset breast cancer patients: African American compared to White Women. J Med Genet 2005.
7. Malone KE, Daling JR, Doody DR et al. Prevalence and predictors of BRCA1 and BRCA2 mutations in a population-based study of breast cancer in white and black American women ages 35 to 64 years. Cancer Res 2006; 66: 8297-8308.
8. Pal T, Permuth-Wey J, Holtje T et al. BRCA1 and BRCA2 mutations in a study of African American breast cancer patients. Cancer Epidemiol Biomarkers Prev 2004; 13: 1794-1799.
9. Huo D, Olopade OI. Genetic testing in diverse populations: Are researchers doing enough to get out the correct message? JAMA 2007; 298: 2910-2911.
10. John EM, Miron A, Gong G et al. Prevalence of pathogenic BRCA1 mutation carriers in 5 US racial/ethnic groups. JAMA 2007; 298: 2869-2876.
11. Nanda R, Schumm LP, Cummings S et al. Genetic testing in an ethnically diverse cohort of high-risk women: A comparative analysis of BRCA1 and BRCA2 mutations in American families of European and African ancestry. JAMA 2005; 294: 1925-1933.
12. Ahn SH, Son BH, Yoon KS et al. BRCA1 and BRCA2 germline mutations in Korean breast cancer patients at high risk of carrying mutations. Cancer Lett 2007; 245: 90-95.
13. Choi DH, Cho DY, Lee MH et al. The CHEK2 1100delC mutation is not present in Korean patients with breast cancer cases tested for BRCA1 and BRCA2 mutation. Breast Cancer Res Treat 2008.
14. Choi DH, Lee MH, Bale AE et al. Incidence of BRCA1 and BRCA2 mutations in young Korean breast cancer patients. J Clin Oncol 2004; 22: 1638-1645.
15. Frank TS, Manley SA, Olopade OI et al. Sequence analysis of BRCA1 and BRCA2: Correlation of mutations with family history and ovarian cancer risk. J Clin Oncol 1998; 16: 2417-2425.
16. Frank TS. Laboratory determination of hereditary susceptibility to breast and ovarian cancer. Arch Pathol Lab Med 1999; 123: 1023-1026.
17. Szabo C, Masiello A, Ryan JF et al. The breast cancer information core: database design, structure, and scope. Hum Mutat 2000; 16: 123-131.
18. Harris LN, Broadwater G, Lin NU et al. Molecular subtypes of breast cancer in relation to paclitaxel response and outcomes in women with metastatic disease: Results from CALGB 9342. Breast Cancer Res 2006; 8: R66.
19. Lund MJ, Trivers KF, Porter PL et al. Race and triple negative threats to breast cancer survival: A population-based study in Atlanta, GA. Breast Cancer Res Treat 2009; 113(2): 357-370.
20. Haffty BG, Yang Q, Reiss M et al. Locoregional relapse and distant metastasis in conservatively managed triple negative early-stage breast cancer. J Clin Oncol 2006; 24(36): 5652-5657.
21. Cancer risks in BRCA2 mutation carriers. The Breast Cancer Linkage Consortium. J Natl Cancer Inst 1999; 91: 1310-1316.
22. Easton DF, Bishop DT, Ford D et al. Genetic linkage analysis in familial breast and ovarian cancer: Results from 214 families. The Breast Cancer Linkage Consortium. Am J Hum Genet 1993; 52: 678-701.
23. Ford D, Easton DF, Peto J. Estimates of the gene frequency of BRCA1 and its contribution to breast and ovarian cancer incidence. Am J Hum Genet 1995; 57: 1457-1462.
24. Robson M. Breast cancer surveillance in women with hereditary risk due to BRCA1 or BRCA2 mutations. Clin Breast Cancer 2004; 5: 260-268; discussion 269-271.
25. Bagby GC, Alter BP. Fanconi anemia. Semin Hematol 2006; 43: 147-156.
26. Fackenthal JD, Olopade OI. Breast cancer risk associated with BRCA1 and BRCA2 in diverse populations. Nat Rev Cancer 2007; 7: 937-948.
27. Ferla R, Calo V, Cascio S et al. Founder mutations in BRCA1 and BRCA2 genes. Ann Oncol 2007; 18 (Suppl 6): Vi93-vi98.
28. Kauff ND, Barakat RR. Risk-reducing salpingo-oophorectomy in patients with germline mutations in BRCA1 or BRCA2. J Clin Oncol 2007; 25: 2921-2927.
29. Metcalfe KA, Finch A, Poll A et al. Breast cancer risks in women with a family history of breast or ovarian cancer who have tested negative for a BRCA1 or BRCA2 mutation. Br J Cancer 2009; 100(2): 421-425.
30. Turnbull C, Rahman N. Genetic predisposition to breast cancer: Past, present, and future. Annu Rev Genomics Hum Genet 2008; 9: 321-345.
31. American Society of Clinical Oncology policy statement update: Genetic testing for cancer susceptibility. J Clin Oncol 2003; 21: 2397-2406.
32. Kauff ND, Satagopan JM, Robson ME et al. Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med 2002; 346: 1609-1615.
33. Narod SA, Brunet JS, Ghadirian P et al. Tamoxifen and risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers: A case-control study. Hereditary Breast Cancer Clinical Study Group. Lancet 2000; 356: 1876-1881.
34. Offit K, Robson M, Schrag D. Prophylactic mastectomy in carriers of BRCA mutations. N Engl J Med 2001; 345: 1498-1499; discussion 1499-1500.
35. Olopade OI, Artioli G. Efficacy of risk-reducing salpingo-oophorectomy in women with BRCA-1 and BRCA-2 mutations. Breast J 2004; 10 (Suppl 1): S5-S9.
36. Pierce LJ, Levin AM, Rebbeck TR et al. Ten-year multi-institutional results of breast-conserving surgery and radiotherapy in BRCA1/ 2-associated stage I/II breast cancer. J Clin Oncol 2006; 24: 2437-2443.
37. Rebbeck TR, Friebel T, Lynch HT et al. Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: The PROSE Study Group. J Clin Oncol 2004; 22: 1055-1062.
38. Robson M, Svahn T, McCormick B et al. Appropriateness of breast-conserving treatment of breast carcinoma in women with germline mutations in BRCA1 or BRCA2: A clinic-based series. Cancer 2005; 103: 44-51.
39. Vogel KJ, Atchley DP, Erlichman J et al. BRCA1 and BRCA2 genetic testing in Hispanic patients: Mutation prevalence and evaluation of the BRCAPRO risk assessment model. J Clin Oncol 2007; 25: 4635-4641.
40. Lee E, McKean-Cowdin R, Ma H et al. Evaluation of unclassified variants in the breast cancer susceptibility genes BRCA1 and BRCA2 using five methods: Results from a population-based study of young breast cancer patients. Breast Cancer Res 2008; 10: R19.
41. Tavtigian SV, Byrnes GB, Goldgar DE et al. Classification of rare missense substitutions, using risk surfaces, with genetic- and molecular-epidemiology applications. Hum Mutat 2008; 29: 1342-1354.
42. Couch FJ, Rasmussen LJ, Hofstra R et al. Assessment of functional effects of unclassified genetic variants. Hum Mutat 2008; 29: 1314-1326.
43. Chang J, Hilsenbeck SG, Sng JH et al. Pathological features and BRCA1 mutation screening in premenopausal breast cancer patients. Clin Cancer Res 2001; 7: 1739-1742.
44. Kurian AW, Gong GD, Chun NM et al. Performance of BRCA1/2 mutation prediction models in Asian Americans. J Clin Oncol 2008; 26(29): 4752-4758.
45. Whittemore AS, Gong G, John EM et al. Prevalence of BRCA1 mutation carriers among U.S. non-Hispanic Whites. Cancer Epidemiol Biomarkers Prev 2004; 13: 2078-2083.
46. Prevalence and penetrance of BRCA1 and BRCA2 mutations in a populationbased series of breast cancer cases. Anglian Breast Cancer Study Group. Br J Cancer 2000; 83: 1301-1308.